Public Private Partnerships and Health

  • Sandy A. JohnsonEmail author


There is an increasing amount of interaction between the public and private sectors in economic and human development . The private sector is involved in areas previously the domain of public sector actors and IGOs, through avenues that include charitable contributions and partnerships with public agencies. As a result, the number of global public-private partnerships (GPPP) operating in global health and development is growing. Such partnerships can result in innovative, multi-sectoral strategies that redress a dearth of technological and fiscal resources. Although public and private actors have tried to create common operational structures and principles, these frameworks remain fragmented. Positive outcomes of this trend towards public-private partnerships include money available to global health projects has quadrupled since 1990, and the availability of certain drugs and vaccinations in the developing world increased. But the growth of GPPPs has also given private corporations considerable power in formulating global health policy. Evaluation of the short- and long-term impacts of these partnerships is only now beginning in earnest. Much remains to be seen as to the ultimate gains and losses associated with those partnerships.


Private Sector World Trade Organization Global Fund Private Actor Artemisinin Combination Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Associated Press. (2007). Brazil to break Merck AIDS drug patent: Government wants lower price on anti-retroviral medication. MSNBC. Accessed May 2, 2010.
  2. Avert. (2010). AIDS, drug prices and generic drugs Accessed on May 2, 2010.
  3. Bodenheimer, T., & Grumbach, K. (2008). Understanding health policy: A clinical approach (5th ed.). New York: McGraw-Hill Medical.Google Scholar
  4. Buse, K., & Walt, G. (2000a). Global public-private partnerships: Part I—A new development in Health. Bull. W.H.O., 78(4), 549–561.Google Scholar
  5. Buse, K., & Walt, G. (2000b). Global public-private partnerships: Part II—what are the health issues for global governance? Bull. W.H.O., 78(5), 699–709.Google Scholar
  6. Department of Health and Human Services. (2001). The globalization of clinical trials: A growing challenge in protecting human subjects. Accessed April 25, 2010.
  7. The Economist. (2010). Spoonful of Ingenuity. The Economist. January 7.Google Scholar
  8. Garrett, L. (2007). The Challenge of Global Health. Foreign Affairs. Accessed January 9, 2010.
  9. GAVI Alliance. (2010) Accessed April 19, 2010.
  10. GAVI Secretariat. (2006). GAVI Alliance Strategy (2007–10). Accessed April 3, 2010.
  11. Glickman, S., McHutchison, J., Peterson, E., Cairns, C., Harrington, R., Califf, R., et al. (2009). Ethical and scientific implications of the globalization of clinical research. The New England Journal of Medicine, 360(8), 816–823.CrossRefGoogle Scholar
  12. Global Fund. (2010). The global fund: To fight AIDS, tuberculosis and malaria. Accessed May 21, 2010.
  13. Institute for Health Metrics and Evaluation (IHME). Financing Global Health. (2015). Development assistance steady on the path to new Global Goals (p. 2016). Seattle, WA: IHME.Google Scholar
  14. Joint United Nations Programme on HIV/AIDS (UNAIDS). (1998). Access to drugs: UNAIDS technical update. United Nations. Accessed April 2, 2010.
  15. Joint United Nations Programme on HIV/AIDS (UNAIDS). (2008). UNAIDS: the first 10 years, 1996–2007. UNAIDS/07.20E/JC126E. Geneva: UNAIDS.Google Scholar
  16. Joint United Nations Programme on HIV/AIDS (UNAIDS). (2009). Composition of the programme coordinating board. United Nations. Accessed April 23, 2010.
  17. Joint United Nations Programme on HIV/AIDS (UNAIDS). (2010). The governance handbook. Geneva: UNAIDS.Google Scholar
  18. Loewenberg, S. (2008). Drug company trials come under increasing scrutiny. Lancet, 371, 191–192.CrossRefGoogle Scholar
  19. Lopez, A., Mathers, C., Ezzati, M., Jamison, D., & Murray, C. (Eds.). (2006). Global burden of disease and risk factors. New York: Oxford University Press.Google Scholar
  20. Lurie, P., & Wolfe, S. M. (1997). Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. The New England Journal of Medicine, 337(12), 853–856.CrossRefGoogle Scholar
  21. Mathews, J. (2009). Power Shift. In R. W. Mansbach & E. Rhodes (Eds.), Global politics in a changing world (pp. 200–209). Boston: Houghton Mifflin Harcourt Publishing Company.Google Scholar
  22. Mectizan® Donation Program. (2009). Accessed April 20, 2010.
  23. Unit, N. G. O., & Development, Social. (1998). The bank’s relations with NGOs: Issues and directions. Washington, D.C.: The Social Development Family of the World Bank.Google Scholar
  24. Nundy, S., & Gulhati, C. M. (2005). A new colonialism?—conducting clinical trials in India. The New England Journal of Medicine, 352(16), 1633–1636.CrossRefGoogle Scholar
  25. Samarasinghe, SWR. (2010). Personal communication. April 19, 2010.Google Scholar
  26. Shapiro, H. T., & Meslin, E. M. (2001). Ethical issues in the design and conduct of clinical trials in developing countries. The New England Journal of Medicine, 345(2), 139–142.CrossRefGoogle Scholar
  27. Simmons, P. J. (2009). Learning to live with NGOs. In R. W. Mansbach & E. Rhodes (Eds.), Global politics in a changing world (pp. 210–215). Boston: Houghton Mifflin Harcourt Publishing Company.Google Scholar
  28. UNAIDS—See Joint United Nations Programme on HIV/AIDS.Google Scholar
  29. UN Global Compact Office. (2008). United Nations global compact: corporate citizenship in the world economy. United Nations. Accessed April 20, 2010.
  30. Wilson, D., Cawthorne, P., Ford, N., & Aongsonwang, S. (1999). Global trade and access to medicine: AIDS treatment in Thailand. Lancet, 354, 1893–1895.CrossRefGoogle Scholar
  31. World Commission on Environment and Development. (1987). Report of the world commission on environment and development: Our common future. Accessed May 18, 2010.
  32. World Health Organization. (1998). Selected topics in health reform and drug financing—health economics and drugs. WHO/DAP/98.3. Geneva: World Health Organization.Google Scholar
  33. World Health Organization. (1999). WHO guidelines on collaboration and partnerships with commercial enterprises. Draft discussion document. Geneva: World Health Organization. Cited by Buse & Walt, (2000a), pg. 555.Google Scholar
  34. World Health Organization. (2010). Control of Neglected Tropical Diseases. World Health Organization. February 21, 2010.
  35. World Health Organization, United Nations Children’s Fund, and UNAIDS. (2010). Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: Progress report 2008. Accessed June 23, 2010.

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Josef Korbel School of International StudiesUniversity of DenverDenverUSA

Personalised recommendations